Table 5.

Estimates of OS (time from start of GTX therapy to death) for patients who received their first line of GTX

	N	Median OS (months)	1 year OS	HR	95% CI	P
All patients	79	11.6	46 (34, 62)
All patients, by staging
LAPC	29	25.03	56 (37, 84)	1.00	–
Mets	50	11.3	42 (28, 62)	1.37	(0.6, 3.13)	0.461
Grade
Well or moderately differentiated	15	21.93	60 (36, 100)	1.00	–
Poorly differentiated or unknown	64	11.3	43 (30, 61)	1.29	(0.51, 3.27)	0.595
ECOG
0	28	23.23	64 (44, 94)	1.00	–
1+	50	9.9	38 (25, 58)	2.57	(1.03, 6.41)	0.043
Prior surgery
Yes	4	14.27	100 (100, 100)	1.00	–
No	44	9.9	42 (26, 69)	0.84	(0.08, 9.29)	0.886
Hospitalizations
None	32	14.27	51 (31, 83)	1.00	–
1 or more	15	11.3	44 (21, 89)	0.84	(0.22, 3.19)	0.8
Any grade 3/4 toxicity
No	47	11.7	48 (33, 69)	1.00	–
Yes	31	9.9	41 (24, 70)	1.03	(0.5, 2.13)	0.928
Family history of cancer
No	19	8.87	10 (2, 61)	1.00	–
Yes	57	14.27	59 (46, 76)	0.61	(0.27, 1.35)	0.221
Comorbidities
None	10	14.27	86 (63, 100)	1.00	–
1 or more	38	9.5	31 (15, 65)	2.74	(0.45, 16.56)	0.273
Neutropenia
No	22	9.5	47 (26, 85)	1.00	–
Yes	42	12.13	52 (36, 74)	1.00	(0.39, 2.52)	0.994
Elevated ALT
No	24	8.07	32 ((15, 69)	1.00	–
Yes	53	13.3	52 (38, 71)	0.73	(0.34, 1.56)	0.42
Change in CA19 from baseline
<25%	20	7.97	39 (19, 76)	1.00	–
25–50%	20	12.13	51 (31, 84)	0.76	(0.26, 2.22)	0.582
50–75%	13	9.03	25 (8, 83)	1.19	(0.38, 3.73)
>75%	12	13.3	62 (38, 100)	0.56	(0.18, 1.76)
RECIST-based response
Partial response	14	21.93	65 (42, 100)	1.00	–
Stable disease	50	12.13	51 (35, 73)	2.03	(0.7, 5.93)
Progressive disease	12	7.93	10 (2, 65)	6.32	(1.74, 22.9)	0.017
Missing	3	4.6	33 (7, 100)

Values are OS (95% CI)

LAPC locally advanced pancreatic cancer